Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may increase the risk of pulmonary aspiration among patients undergoing surgery ...
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
Companies focused on diabetes and obesity such as Teladoc and Omada Health have embraced glucagon-like peptide-1 agonist drugs while dangling the prospect of lowered costs to their employer customers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback